Midatech Pharma PLC (AIM:MTPH.L, NASDAQ:MTP) will announce its interim results for the six months ended 30 June 2020 on 10 September 2020. The company is focused on improving the bio-delivery and biodistribution of medicines using its proprietary drug delivery technologies. An investor conference call will be held at 2.00pm on the day of the results, with further details to follow. Midatech has developed three technology platforms aimed at enhancing medication delivery and has a strong patent portfolio supporting its innovations.
Midatech Pharma PLC announced the issuance of 500,000 American Depositary Shares (ADSs), equivalent to 2,500,000 ordinary shares, due to the exercise of warrants by U.S. investors at $2.05 per ADS. This results in gross proceeds of $1,025,000 for the company. The admission of the new shares is anticipated on August 21, 2020. Post-issuance, the total issued share capital will comprise 63,048,852 ordinary shares. Midatech focuses on enhancing drug delivery systems through innovative technologies, supported by a significant number of patents.
Midatech Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP) announced on August 14, 2020, that the SEC has declared effective its registration statement on Form F-1. This allows for the resale of 12,695,445 ordinary shares represented by 2,539,091 American Depositary Shares (ADSs) held by certain stockholders. These shares include warrants from US Registered Direct Offerings executed in October 2019 and May 2020. The company will not receive proceeds from these sales, although it will benefit from the exercise of the warrants.
Midatech Pharma PLC announced that the U.S. SEC has declared effective its registration statement on Form F-1 for the resale of up to 12,695,445 ordinary shares, represented by 2,539,091 American Depositary Shares (ADSs). These shares are connected to multiple warrant exercises at various prices, including $6.25 and $2.05 per ADS. While the registration allows stockholders to sell their ADSs or ordinary shares, the company will not receive proceeds from these sales. However, it will receive funds upon the cash exercise of the warrants. Additional details are available on the SEC's website.